Independent pharmacies continued to grow in both overall sales and prescription volume, according to the 1999 NCPA-Searle Digest, which reports 1998 data. The Digest compiles and summarizes comprehensive financial data from independent pharmacies nationwide. Participating pharmacies evaluate their stores' financial performance based on revenues, expenses and other demographic information.
Independent pharmacies continued to grow in both overall sales and prescription volume, according to the 1999 NCPA-Searle Digest, which reports 1998 data. The Digest compiles and summarizes comprehensive financial data from independent pharmacies nationwide. Participating pharmacies evaluate their stores' financial performance based on revenues, expenses and other demographic information.
Independent pharmacy sales have soared by more than 20% over the last two years according to the Digest, with pharmacy sales averaging $1.75 million in 1998. Prescription sales revenue also grew, accounting for 82% ($1.43 million) of total average sales â up 9.5% from last year.
Prescription volume also increased, going up by 6,000 prescriptions over the past two years and reaching 46,000 prescriptions dispensed per pharmacy in 1998.
Other key findings cited in the study:
• The average proprietor or manager's total income increased to more than $141,000.
• The percentage of total prescriptions covered by Medicaid and other third-party programs continues to increase, rising to 71% from 67% the previous year.
• Gross margin decreased as a percentage of sales to 24.9%. Net profit represented 3.1% of sales.
"The results of the Digest survey prove that enterprising independent pharmacists are continuing to find ways to grow their business and control their costs," said Whitaker Moose, president of the National Community Pharmacists Association. "We continue to see pharmacists expanding their practices into disease state management and offering their patients more and better services. These are all indicators that independent pharmacies are well-positioned for success in the new millennium." PR
The Weight-Loss Gold Rush: Legal and Regulatory Implications
July 11th 2024Jim Shehan, chair of the FDA Regulatory practice, Lowenstein Sandler, discusses how the FDA and other regulators likely to respond to the increased public interest and potential off-label use of GLP-1 drugs, what needs to be done for GLP-1s to be covered, advice for investors and financiers considering entering the weight-loss medication market and more.
Healthcare Marketing Strategies for Reaching Diverse Audiences
May 14th 2024Amanda Powers-Han, Chief Marketing Officer, Greater Than One, and Pharmaceutical Executive Editorial Advisory Board member, discusses how improved DE&I in healthcare marketing strategies can not only reach diverse audiences more effectively but also contribute to improved patient care outcomes, challenges faced in crafting culturally sensitive messages, and much more.